Intellia Therapeutics (NTLA) Tops Q1 EPS by 23c

Intellia Therapeutics (NASDAQ: NTLA) reported Q1 EPS of ($1.17), $0.23 better than the analyst estimate of ($1.40). Revenue for the quarter came in at $12.61 million versus the consensus estimate of $11.66 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
• Signet shares jump on Q2 profit beat, raised annual guidance
• Korn Ferry (KFY) Tops Q1 EPS by 7c, Beats on Revenue; Offers Q2 EPS Guidance